Timothy Rolph Sells 12,500 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 12,500 shares of Akero Therapeutics stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $43.43, for a total value of $542,875.00. Following the sale, the insider now directly owns 169,721 shares in the company, valued at $7,370,983.03. The trade was a 6.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $41.03, for a total transaction of $256,437.50.
• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $35.88, for a total transaction of $224,250.00.
• On Wednesday, March 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.53, for a total value of $556,625.00.

Akero Therapeutics Trading Down 0.3 %

Shares of Akero Therapeutics stock opened at $42.66 on Friday. Akero Therapeutics, Inc. has a 12-month low of $17.86 and a 12-month high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $3.40 billion, a P/E ratio of -11.38 and a beta of -0.12. The stock has a fifty day simple moving average of $41.31 and a 200 day simple moving average of $37.36.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). On average, sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors have recently made changes to their positions in AKRO. abrdn plc raised its position in Akero Therapeutics by 118.7% during the 4th quarter. abrdn plc now owns 269,782 shares of the company’s stock valued at $7,505,000 after purchasing an additional 146,424 shares during the last quarter. Rock Springs Capital Management LP boosted its position in shares of Akero Therapeutics by 1.4% in the 4th quarter. Rock Springs Capital Management LP now owns 946,499 shares of the company’s stock worth $26,332,000 after purchasing an additional 13,100 shares in the last quarter. Sei Investments Co. bought a new position in Akero Therapeutics in the 4th quarter worth about $303,000. Charles Schwab Investment Management Inc. raised its stake in shares of Akero Therapeutics by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company’s stock worth $15,042,000 after purchasing an additional 8,096 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Akero Therapeutics by 14.0% in the fourth quarter. Wells Fargo & Company MN now owns 61,867 shares of the company’s stock worth $1,721,000 after purchasing an additional 7,587 shares during the last quarter.

Wall Street Analysts Forecast Growth

AKRO has been the subject of a number of analyst reports. Morgan Stanley restated an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. UBS Group upped their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Citigroup lifted their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Canaccord Genuity Group upped their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Finally, HC Wainwright boosted their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Monday, March 3rd. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $76.29.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.